Cara Therapeutics, Inc. (0HTC.L)
USD 0.25
(-1.15%)
USD 0.25
(-1.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -117.65 Million USD | -38.5% |
| 2022 | -83.8 Million USD | 1.74% |
| 2021 | -88.19 Million USD | -1692.47% |
| 2020 | 5.59 Million USD | 105.01% |
| 2019 | -111.48 Million USD | -44.32% |
| 2018 | -77.01 Million USD | -30.09% |
| 2017 | -58.99 Million USD | -1.86% |
| 2016 | -56.93 Million USD | -131.86% |
| 2015 | -24.34 Million USD | -39.38% |
| 2014 | -17.28 Million USD | -7525.32% |
| 2013 | 552 Thousand USD | 95.46% |
| 2012 | -5.21 Million USD | 37.89% |
| 2011 | -8.57 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -16.13 Million USD | 37.12% |
| 2024 Q1 | -27.22 Million USD | 9.41% |
| 2023 Q3 | -28.03 Million USD | 13.16% |
| 2023 Q1 | -27.59 Million USD | 11.87% |
| 2023 FY | - USD | -38.5% |
| 2023 Q2 | -32.28 Million USD | -16.99% |
| 2023 Q4 | -32.52 Million USD | -16.03% |
| 2022 FY | - USD | 1.74% |
| 2022 Q4 | -31.3 Million USD | -31.29% |
| 2022 Q3 | -23.84 Million USD | -440.83% |
| 2022 Q2 | -4.4 Million USD | 84.17% |
| 2022 Q1 | -27.84 Million USD | 16.93% |
| 2021 Q4 | -33.52 Million USD | -3056.5% |
| 2021 Q2 | -30.81 Million USD | -31.14% |
| 2021 FY | - USD | -1692.47% |
| 2021 Q1 | -23.49 Million USD | -129.99% |
| 2021 Q3 | -1.06 Million USD | 96.55% |
| 2020 Q4 | 78.35 Million USD | 561.74% |
| 2020 Q3 | -16.96 Million USD | 34.32% |
| 2020 Q2 | -25.83 Million USD | 13.74% |
| 2020 Q1 | -29.95 Million USD | 0.06% |
| 2020 FY | - USD | 105.01% |
| 2019 Q1 | -23.08 Million USD | -5.04% |
| 2019 FY | - USD | -44.32% |
| 2019 Q2 | -24.09 Million USD | -4.37% |
| 2019 Q3 | -34.38 Million USD | -42.72% |
| 2019 Q4 | -29.97 Million USD | 12.83% |
| 2018 FY | - USD | -30.09% |
| 2018 Q4 | -21.97 Million USD | -7.79% |
| 2018 Q3 | -20.38 Million USD | -15.2% |
| 2018 Q2 | -17.69 Million USD | -4.12% |
| 2018 Q1 | -16.99 Million USD | -16.66% |
| 2017 Q3 | -12.83 Million USD | -34.92% |
| 2017 Q2 | -9.51 Million USD | 57.17% |
| 2017 Q4 | -14.57 Million USD | -13.56% |
| 2017 Q1 | -22.2 Million USD | 0.5% |
| 2017 FY | - USD | -1.86% |
| 2016 Q2 | -12.8 Million USD | -24.87% |
| 2016 FY | - USD | -131.86% |
| 2016 Q4 | -22.31 Million USD | -91.12% |
| 2016 Q3 | -11.67 Million USD | 8.83% |
| 2016 Q1 | -10.25 Million USD | -5.42% |
| 2015 Q3 | -4.81 Million USD | 13.07% |
| 2015 Q2 | -5.53 Million USD | -22.41% |
| 2015 Q1 | -4.52 Million USD | -4.36% |
| 2015 FY | - USD | -39.38% |
| 2015 Q4 | -9.72 Million USD | -102.06% |
| 2014 Q1 | -3.22 Million USD | -53.16% |
| 2014 Q3 | -6.4 Million USD | -82.2% |
| 2014 Q4 | -4.33 Million USD | 32.31% |
| 2014 FY | - USD | -7525.32% |
| 2014 Q2 | -3.51 Million USD | -9.06% |
| 2013 Q2 | 7.11 Million USD | 642.38% |
| 2013 Q4 | -2.1 Million USD | 37.05% |
| 2013 Q1 | -1.31 Million USD | 16.49% |
| 2013 FY | - USD | 95.46% |
| 2013 Q3 | -3.34 Million USD | -146.99% |
| 2012 FY | - USD | 37.89% |
| 2012 Q4 | -1.57 Million USD | -72.45% |
| 2012 Q3 | -911 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 27.874% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1317.153% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 219.731% |
| Perrigo Company plc | 646.2 Million USD | 118.206% |
| Illumina, Inc. | -608 Million USD | 80.65% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.089% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 73.798% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.957% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 103.613% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -13.352% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.528% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -215.559% |
| Waters Corporation | 1.02 Billion USD | 111.509% |
| Biogen Inc. | 2.37 Billion USD | 104.95% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -34.569% |
| Evolus, Inc. | -41.81 Million USD | -181.392% |
| Adicet Bio, Inc. | -136.53 Million USD | 13.832% |
| bluebird bio, Inc. | -167.16 Million USD | 29.619% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 21.623% |
| FibroGen, Inc. | -261.4 Million USD | 54.993% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 107.016% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -164.759% |
| Homology Medicines, Inc. | -47.75 Million USD | -146.356% |
| Geron Corporation | -174.78 Million USD | 32.688% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 48.426% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -27.771% |
| Myriad Genetics, Inc. | -67.8 Million USD | -73.525% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -16.685% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 76.763% |
| Zoetis Inc. | 3.68 Billion USD | 103.193% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -132.639% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 110.107% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 137.917% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.555% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -226.063% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 48.85% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 55.77% |
| Verastem, Inc. | -83.16 Million USD | -41.464% |
| Nektar Therapeutics | -243.1 Million USD | 51.606% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 47.709% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -33.716% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 73.212% |
| OPKO Health, Inc. | -65.51 Million USD | -79.574% |
| Exelixis, Inc. | 196.6 Million USD | 159.842% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 128.274% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 208.609% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -111.009% |
| uniQure N.V. | -253.1 Million USD | 53.516% |
| Imunon, Inc. | -20.78 Million USD | -466.107% |
| Blueprint Medicines Corporation | -474.61 Million USD | 75.211% |
| Insmed Incorporated | -654.73 Million USD | 82.031% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 126.032% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 65.944% |
| TG Therapeutics, Inc. | 26.1 Million USD | 550.766% |
| Incyte Corporation | 919.42 Million USD | 112.796% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 76.717% |